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Abstract
Autism spectrum disorders share three core symptoms: impaired sociability, repetitive behaviors and communication
deficits. Incidence is rising, and current treatments are inadequate. Seizures are a common comorbidity, and since the 1920’s
a high-fat, low-carbohydrate ketogenic diet has been used to treat epilepsy. Evidence suggests the ketogenic diet and
analogous metabolic approaches may benefit diverse neurological disorders. Here we show that a ketogenic diet improves
autistic behaviors in the BTBR mouse. Juvenile BTBR mice were fed standard or ketogenic diet for three weeks and tested for
sociability, self-directed repetitive behavior, and communication. In separate experiments, spontaneous intrahippocampal
EEGs and tests of seizure susceptibility (6 Hz corneal stimulation, flurothyl, SKF83822, pentylenetetrazole) were compared
between BTBR and control (C57Bl/6) mice. Ketogenic diet-fed BTBR mice showed increased sociability in a three-chamber
test, decreased self-directed repetitive behavior, and improved social communication of a food preference. Although
seizures are a common comorbidity with autism, BTBR mice fed a standard diet exhibit neither spontaneous seizures nor
abnormal EEG, and have increased seizure susceptibility in just one of four tests. Thus, behavioral improvements are
dissociable from any antiseizure effect. Our results suggest that a ketogenic diet improves multiple autistic behaviors in the
BTBR mouse model. Therefore, ketogenic diets or analogous metabolic strategies may offer novel opportunities to improve
core behavioral symptoms of autism spectrum disorders.
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Introduction
Estimates indicate that autism spectrum disorder (ASD) affects
at least 1 in 160 individuals [1]. Diagnosis involves three core
symptoms: impaired social interactions, stereotyped repetitive
behaviors and communication deficits [2]. Effective treatments are
lacking for these core symptoms, and pharmacological approaches
often target co-morbidities in the hope that relieving associated
medical issues will yield more general improvements [3]. Seizures
and/or EEG abnormalities are common [4,5], and children with
intractable seizures and autism suffer poor outcomes – even with
aggressive interventions such as brain surgery [6]. Hence, it is of
paramount importance that new, safe and effective treatment
options be developed for ASD.
An effective historical metabolic treatment for refractory
epilepsy is a high-fat, low-carbohydrate ketogenic diet (KD). This
metabolic therapy experienced a resurgence over the past two
decades, and multiple retrospective and prospective studies have
confirmed its ability to dramatically reduce seizures in both
children and adults [7,8]. At a biochemical level, the KD forces a
switch to predominant metabolism of ketones rather than glucose,
and hallmark metabolic effects of the diet include increased blood
ketones, reduced blood glucose, and increased mitochondrial
function. Given the ubiquitous presence of metabolic abnormal-
ities in neurological disorders [9], including autism [10], metab-
olism-based therapies such as the KD are of great interest -
particularly in those diseases with a dearth of effective options.
Furthermore, several putative mechanisms mobilized by the KD
may alleviate autistic symptoms [11–13]. This rationale is
supported by a thus-far singular prospective clinical report, a pilot
study conducted on 30 children four to ten years old [14]. The diet
was applied intermittently (four weeks on and two weeks off) for six
months, and parents evaluated behavior using the Childhood
Autism Rating Scale. Of those children who maintained the diet
(18/30), 11% had significant improvement, 44% average
improvement, and 44% mild improvement. In this initial study,
the biggest improvements were noticed in those patients who
showed only mild autistic behavior. Ketogenic diet therapy for
epilepsy is applied continuously, and improvement potential of a
standard (non-intermittent) regimen in autism has not been
explored prospectively.
The BTBR T+ tf/j (BTBR) strain of mice, developed through
the early and mid-20th century, was recently characterized as
having an autism-like behavioral phenotype [15]. These mice have
low sociability in a number of tests, reduced communication, and
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elevated self-directed behavior compared to typical strains. Here
we tested behavioral effects of a KD in this strain, and also tested
for spontaneous seizures, abnormal EEG, and altered seizure
threshold. We found that the KD improved all three behavioral
deficits significantly [16], and, in contrast to other models of
autism [17,18] the BTBR mouse does not exhibit spontaneous
behavioral or electrographic seizures. Furthermore, BTBR mice
had minor and inconsistent changes in seizure threshold compared
to control mice. Thus, behavioral improvement initiated by the
KD was independent of its well-known antiseizure effects.
Materials and Methods
Ethics Statement
All procedures were performed in accordance with the NIH
Guide for the Care and Use of Laboratory Animals, and approved
by the Institutional Review Boards of Trinity College (A3869–01)
and the Legacy Research Institute (A3234–01).
Animals
At weaning, male BTBR T+ tf/j (Jackson Laboratories, Bar
Harbor, ME) or C57Bl/6 littermates were housed socially (3–6 per
cage). At five weeks of age, cages were assigned randomly to
control diet (CD; LabDiet 5001, W.F. Fisher & Son, Somerville,
NJ) or KD (F3666; BioServ, Frenchtown, NJ) fed ad libitum. All
testing occurred at 8–10 weeks of age, i.e. between 3–5 weeks of
dietary treatment. All measures were taken to minimize animal
suffering.
Behavioral Analysis
To test sociability, a Plexiglas apparatus measuring 22-x-42.5-x-
19 cm with three equal chambers was used. Small wire cages were
placed in the side chambers. Testing occurred as described
previously [15]. Testing occurred in three 10 min phases with free
movement among the three chambers. During phase one, the wire
cages were vacant (a test for side bias). In phase two, a ‘‘stranger’’
mouse (C57Bl/6) was placed in the wire cage of one side chamber
(a test of sociability). During phase three, the first (now familiar)
C57Bl/6 mouse remained in place and a new ‘‘stranger’’ C57Bl/6
mouse was put in the other wire cage (a test for preference for
social novelty). Stranger mouse placement was counterbalanced
between tests. Time spent in each chamber and frontal contact
(nose/face/forepaw contact with the cages and/or stranger mice)
were quantified.
Self-directed repetitive behavior (self-grooming) was quantified
in the three-chamber sociability test and during a separate 10 min
test with mice alone in a small (19-x-29-x-12.5 cm) empty cage on
a different day.
Communication was assessed by social transmission of a food
preference as described previously [15]. Mice were habituated to
eating KD or powdered CD, as appropriate, from glass jars (Dyets,
Inc., Bethlehem, PA). A demonstrator mouse was fasted for 18 h,
and presented with one jar of powdered flavored food (‘‘trained’’
flavor) for 2 h. The demonstrator was returned to the home cage
for 30 min to interact with cage-mate observer mice. Observer
mice were fasted for 18 h, and then presented with both the
‘‘trained’’ flavor (eaten by the demonstrator) and an ‘‘untrained’’
flavor (novel flavored food) for 2 h. Jars were weighed before and
after presentation. Flavor pairs were cocoa (2%) v. cinnamon (1%)
and cinnamon (1%) v. cumin (0.25%).
Blood Chemistry
Several days after completing all behavioral testing, a subset of
mice was anesthetized with isoflurane for tail blood collection.
Whole blood was analyzed for glucose and b-hydroxybutyrate
with Precision Xtra meters (Abbott Laboratories, Bedford, MA).
Intrahippocampal EEG and Seizure Threshold
EEG electrodes were implanted into BTBR and C57Bl/6 mice
at 8 weeks of age. Briefly, bipolar stainless steel electrodes
(insulated except 80–100 mm at the tip; tip diameter 5 mm; vertical
tip separation 200–250 mm; Plastics One Inc., Roanoke, VA) were
implanted bilaterally into hippocampal CA3 using stereotaxic
coordinates (AP =22.18 mm; ML =62.65 mm; DV =22.6 mm
to Bregma). A screw electrode was placed over frontal cortex and a
ground electrode over the cerebellum. Electrodes were secured
with dental cement. After a 3 d recovery period, animals were
recorded continuously for 72 h.
Electrical brain activity was monitored using a Nervus EEG
recording system and a Magnus 32/8 Amplifier (Nervus,
Taugagreining, Iceland), and filtered (high-pass 0.3 Hz, low-pass
100 Hz). The digital EEG signal was analyzed using the LabChart
version 7 software (AD Instruments, Colorado Springs, CO). An
observer unaware of genotype assessed EEG records for seizure
activity, defined by high-amplitude rhythmic discharges lasting for
more than 5 s (repetitive spikes, spike-and-wave discharges, or
slow waves).
Separate groups of mice were tested for seizure susceptibility
(one test per mouse) in one of four seizure models. For electrical
stimulation, after ocular local anesthesia (0.5% tetracaine drops),
seizures were induced via corneal electrodes with a 3 s train of
2 ms duration pulses delivered at 6 Hz (Ugo Basile, Comerio,
Italy). Mice were placed immediately in a standard cage and
observed for 15–20 s for presence or absence of a seizure. Seizure
threshold was determined with the ‘‘up/down’’ method [19]. For
drug-induced seizures, we administered flurothyl (inhaled putative
GABA antagonist; Sigma-Aldrich, St. Louis, MO), pentylenete-
trazole (PTZ; GABA antagonist; Sigma-Aldrich, St. Louis, MO) or
SKF83822 (dopamine D1 agonist; Tocris Bioscience, Bristol, UK).
Flurothyl was infused (20 ml/min) into a Plexiglas chamber (15-x-
20-x-35 cm) and latency to tonic/clonic seizure was recorded.
PTZ was dissolved in saline and injected (i.p.; 50 mg/kg) and mice
were observed for 30 min; peak seizure score was recorded
according to the modified Racine scale. SKF83822 was dissolved
in 5% dimethylsulfoxide in water and injected (s.c.; 2.0 mg/kg)
and mice were observed for 80 min; latency to and number of
seizures were recorded.
Statistical Analysis
Social and grooming behavior were scored from video by two
independent scorers, at least one of whom was blind to treatment.
Inter-rater reliability (Cronbach’s a) for social behavior was 0.998,
and for grooming was 0.997. Sociability data were non-normal
and converted to ranks before analysis. Data were analyzed using
t-test or ANOVA with Newman-Keuls post-hoc tests, except for
6 Hz testing which was analyzed according to Dixon and Mood
[19]. Data are reported as mean 6 standard error. p,0.05 was
considered significant.
Results
After 3–5 weeks on the KD, BTBR mice showed significant
hallmark blood chemistry changes, i.e., having ketonemia (CD:
0.1460.02 mM v. KD: 1.4160.19 mM, p,0.001) and lowered
glucose (CD: 14265 mg/dL v. KD: 9367 mg/dL, p,0.001).
In the three-chamber test of sociability, BTBR mice fed either a
CD or KD showed no inherent side preference (Fig. 1A, phase 1).
As expected, BTBR mice were poorly social: when choosing
Autistic Behaviors Reversed by Ketogenic Diet
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between an empty chamber and a mouse-containing chamber,
CD-fed BTBR mice showed no significant sociability (Fig. 1A,
phase 2). However, KD-fed BTBR mice were significantly and
robustly social when given this choice (Fig. 1A, phase 2). KD did
not influence preference for social novelty (Fig. 1A, phase 3). The
KD had no significant effect on sociability or preference for social
novelty in highly social C57Bl/6 control mice (data not shown).
Upon further analysis of phase 3, we found that time spent in
frontal contact with the mouse-containing cages in phase 3 was
increased significantly in KD-fed mice (Fig. 1B). Therefore,
treatment with a KD improved sociability in phases 2 and 3 of
the three-chamber test as assessed by chamber time and frontal
contact time, respectively.
In addition to increasing sociability in the three-chamber test,
KD-feeding decreased self-directed repetitive behaviors as quan-
tified by time spent grooming. In the absence of other mice (phase
1) there was no diet-related difference in grooming (Fig. 1C). After
introducing other mice (phases 2 and 3), however, grooming time
increased in CD-fed BTBRs, yet did not change in KD-fed
animals. Thus the KD mice spent less time on this self-directed
repetitive behavior than CD-fed during phases 2 and 3. In single
small chamber tests of grooming, KD feeding did not significantly
influence the time spent grooming (CD: 142614 s; KD:
126619 s, n.s.). Therefore, the KD appears to significantly reduce
self-directed behavior in social but not in non-social situations in
BTBR mice. The KD did not significantly affect grooming in
Figure 1. A KD reduces symptoms of autism in BTBR mice. (A) KD increases social interactions in the three-chamber test of sociability. During
phase 2, CD-fed mice did not spend significantly more time with a mouse-containing versus an empty chamber (middle). However, KD-fed mice
preferred spending time in the chamber with a mouse (middle). During phase 3, diet did not affect preference for social novelty (right). Diet
F(1,112) = 8.9, p,0.01; Social situation F(2,112) = 12.5, p,0.001; Diet-by-Social situation interaction F(2,112) = 3.2, p,0.05; n = 28–30. (B) KD feeding
increases sociability as assessed in phase 3 of (A). Although there was no diet-related preference for social novelty, there was a significant diet-related
difference in total time spent in frontal contact with the small wire cages, both of which contained mice. KD-fed mice spent significantly more time in
frontal contact. n = 28–30. (C) KD feeding had no effect during phase 1, but resulted in significantly less self-directed repetitive behavior in phases 2
and 3 as assessed by time spent grooming. Diet F(1,111) = 22.1, p,0.001; Phase F(2,111) = 17.1, p,0.001; Diet-by-Phase interaction F(2,111) = 6.8, p,0.01;
n = 28–30. (D) KD feeding improves communication as assessed by the transmission of a food preference through social interaction; KD-fed mice ate
significantly more of the trained flavor. Diet F(1,33) = 42.5, p,0.001; Flavor F(1,33) = 2.6, n.s.; Diet-by-Flavor interaction F(1,33) = 6.8, p,0.05; n = 17–18.
***p,0.001, CD v. KD; 11p,0.01, 111p,0.001 v. baseline (phase 1).
doi:10.1371/journal.pone.0065021.g001
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control mice in the 3-chamber or single chamber tests (data not
shown).
The KD enhanced social communication of food preference in
BTBR mice. KD-fed BTBR mice ate significantly more of the
‘‘trained’’ detected previously on a littermate (demonstrator;
Fig. 1D). CD-fed BTBR mice, as expected, showed no flavor
preference. Therefore, in the BTBR mouse, the KD improved
sociability and communication, and reduced self-directed repeti-
tive behavior – thus alleviating significantly all three core
hallmarks of ASD. The KD did not significantly affect social
transmission of food preference in control mice in the 3-chamber
or single chamber tests (data not shown).
Although seizures and/or abnormal EEG are often comorbid
with autism, seizures have never been reported in BTBR mice,
and we never observed an overt seizure during videotaped testing,
routine handling, or within the home cage (data not shown). The
absence of behavioral seizures, however, does not eliminate the
possibility of electrographic abnormalities or altered seizure
thresholds. For example, mouse models that show neither
behavioral seizures nor abnormalities with scalp electrodes do
show spontaneous electrographic seizures when assessed with
intrahippocampal electrodes [20]. Here we did not find any
evidence of electrographic seizures in hippocampal CA3 region in
BTBR mice (or, as expected, in control C57Bl/6 mice; Fig. 2).
To assess seizure susceptibility, we used acute electrical and
chemical seizure tests in BTBR and control mice (Fig. 3). In the
6 Hz test, BTBR mice were more sensitive; however, three weeks
of KD-feeding did not alter this threshold (Fig. 3A). BTBR mice
were not different from control mice in their sensitivity (latency) to
flurothyl (Fig. 3B) or their response to PTZ-induced seizures
(Fig. 3C), demonstrating consistent results between these two
GABA antagonists. Finally, BTBR mice were less sensitive (longer
latency) to seizures induced by the dopamine D1 agonist
SKF83822. BTBR mice thus have inconsistent changes in seizure
threshold and a provocation-dependent seizure phenotype.
Furthermore, in the one test with a decreased seizure threshold
(6 Hz) the KD did not influence this susceptibility (Fig. 3A).
Discussion
Here we show that the KD improves behavioral symptoms of
ASD in BTBR mice – a model of autism that presents the three
core deficits of ASD: reduced sociability and communication, and
increased repetitive behavior. These results represent the first time
that an established and effective dietary intervention demonstrates
significant behavioral benefits in a mouse model of autism.
Further, we demonstrate that BTBR mice do not have spontane-
ous behavioral or electrographic seizures and show minor and
inconsistent changes in seizure threshold compared to control
mice. Thus these findings characterize the seizure phenotype – i.e.
lack thereof - of the BTBR mouse, and dissociate the behavioral
changes in this mouse model of autism from the prevalent
comorbidity of seizures or abnormal EEGs found in patients with
autism. We further show that the KD does not alter seizure
susceptibility to 6 Hz stimulation, the only test where seizure
threshold was lower in BTBR mice. Thus, the beneficial
Figure 2. BTBR mice have normal electrical brain activity comparable to control mice. Cortical and intrahippocampal CA3 EEG traces from
BTBR (right panels) and control C57Bl/6 (left panels) mice (n = 4/strain) recorded continuously for 72 h. Upper traces within each brain region are
representative recordings of a 1 min period; lower traces are a higher resolution excerpt of the first 4 s from the respective upper trace. Throughout
the 72 h recording period there was no evidence of electrographic seizures or any other pathological brain activity as determined by comparing the
spike pattern, amplitude and frequency between the BTBR and C57Bl/6 EEGs.
doi:10.1371/journal.pone.0065021.g002
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behavioral effects of the KD are not secondary to its well-known
efficacy against epilepsy and seizure activity. Furthermore, the KD
did not influence sociability or repetitive behavior in control mice,
thus ruling out non-specific effects on these behaviors associated
with autism.
Despite this dissociation from the KD’s anti-seizure properties,
mechanistic changes induced by the KD - some postulated to
underlie its ability to reduce seizures - might be responsible for
behavioral improvements. These mechanisms include the ability of
the KD to reduce reactive oxygen species [21,22], and inflamma-
tion [23–26], both noted to be increased in autism [27,28]. Other
inhibitory mechanisms that could reduce seizures and address
anxiety – both comorbidities in autism - include increased
neuronal inhibition, possibly via reduced glutamate release
[29,30], KATP channel activation [31–33], or increased GABAer-
gic or adenosinergic inhibition [34,35]. Recent investigations of
the KD and autism have suggested that an increase in the
inhibitory neuromodulator adenosine could yield a multiplicity of
effects, including improved sleep, and reduced seizures, sensory
disturbances and anxiety [20,36,37]. At this juncture, however, it
is unknown how key metabolic changes produced by the KD – i.e.,
increased ketone production, reduced glucose, and increased
energy capacity – might causally affect behaviors associated with
ASD and more research is needed.
Beyond hypothesized antiseizure mechanisms of the KD, it is
possible that some of the present results arise from a KD-related
social anxiolytic effect. Mild stress increases grooming [38] and an
increase in grooming by CD-fed BTBR mice in the presence of an
unfamiliar mouse could signal social anxiety. BTBR mice are
known to be more anxious than other strains in tests involving
other animals, but not in more common tests for open space-
related anxiety [39]. Studies of the KD in rats and other mouse
strains have found varying results using these latter tests, but in
humans, overall anxiety scores are improved with a KD [40,41].
In general, amelioration of anxiety by the KD could play a role in
normalizing social interactions in the three-chamber test. Howev-
er, we provide some general evidence that reduced anxiety was not
the only factor. First, the KD did not affect behavior in C57Bl/6
mice. Second, social transmission of food preference was also
improved in BTBR mice by KD-feeding. Because this test involves
communication among familiar cage-mates it involves presumably
low-anxiety interactions. Regardless, anxiety is common in ASD
[42] and an anxiolytic effect of the KD could be beneficial.
Diverse diet-based therapies are popular for ASD, but clear
clinical evidence confirming efficacy is often lacking [43]. Here,
ASD symptoms were alleviated in response to a KD, a treatment
with clear – and sometimes dramatic - efficacy in epilepsy [7,8,44].
These results comport with published predictions [11,12] and one
report that an intermittent KD improved behavior in children
with autism as quantified by the Childhood Autism Rating Scale
[14]. Nevertheless, the present study is the first to demonstrate
improved symptomatology due to a medically established dietary
treatment in a mouse model of autism.
Based on these results, additional research on KDs or analogous
metabolism-based strategies should be considered as we continue
to seek novel and effective treatments for ASD. Immediate
opportunities present themselves when ASD is co-morbid with a
challenging case of epilepsy: in addition to reducing seizures, the
KD could also significantly improve core symptoms of autism. As
noted previously, children with autism and refractory epilepsy
suffer poor outcomes [6], and a KD could offer dual benefits in
this difficult clinical population. Consistent with a growing interest
in metabolic underpinnings of neurological disorders, there has
been increased basic research activity involving KDs and a
dramatic increase in the number of clinical centers worldwide that
administer the KD and its variants [45–47]. In conclusion, the
present research identifies ASD as another potential major
therapeutic target for metabolic strategies like the KD.
Figure 3. BTBR mice exhibit a varied seizure phenotype. (A) In
response to 6 Hz electroconvulsive shocks, BTBR mice had a
significantly reduced threshold compared to control mice, and this
reduction was unaffected by KD feeding. *p,0.05 compared to control;
n = 16 CD group, n = 8 KD group. (B) BTBR mice did not differ from
control mice in latency to tonic/clonic seizures during flurothyl
exposure; n = 7–8. (C) Peak seizure intensity was not different between
BTBR and control mice in response to PTZ injection; n = 10–12. (D)
Latency to first seizure after injection of the dopamine agonist
SKF83822 was reduced in BTBRs, but the number of seizures did not
differ. **p,0.01 compared to controls; n = 9–13.
doi:10.1371/journal.pone.0065021.g003
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